TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity

Marc Cartellieri Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany

Claudia Arndt Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany

Anja Feldmann Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany; Institute of Radiopharmaceutical Cancer Research; Helmholtz-Zentrum Dresden-Rossendorf; Dresden, Germany

Malte von Bonin Medical Clinic and Polyclinic I; University Hospital ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany

Eva-Maria Ewen Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany

Stefanie Koristka Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany

Irene Michalk Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany

Slava Stamova Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany

Nicole Berndt Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany

Anne Gocht Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany

Martin Bornhäuser Medical Clinic and Polyclinic I; University Hospital ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany

Gerhard Ehninger Medical Clinic and Polyclinic I; University Hospital ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany

Marc Schmitz Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany; Center for Regenerative Therapies Dresden; TU Dresden; Dresden, Germany

Michael Bachmann Institute of Immunology; Medical Faculty ‘Carl Gustav Carus’; TU Dresden; Dresden, Germany; Institute of Radiopharmaceutical Cancer Research; Helmholtz-Zentrum Dresden-Rossendorf; Dresden, Germany; Center for Regenerative Therapies Dresden; TU Dresden; Dresden, GermanyCorrespondence[email protected]

show all

Abstract

We have recently described a novel modular targeting platform for T cell recruitment that not only efficiently replaces but also is superior to conventional T cell-engaging bispecific antibodies as it allows for the flexible targeting of several antigens and the delivery of co-stimulatory ligands to malignant lesions, thereby enhancing the antitumor potential of redirected T cells.

Keywords: :

Citation: Cartellieri M, Arndt C, Feldmann A, von Bonin M, Ewen E, Koristka S, Michalk I, Stamova S, Berndt N, Gocht A, et al. TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity. OncoImmunology 2013; 2:e26770; 10.4161/onci.26770

Disclosure of Potential Conflicts of Interest

Michael Bachmann, Slava Stamova, and Gerhard Ehninger have filed provisional patent application related to the antibody directed to CD33.

TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity

Information for

Open access

Opportunities

Help and information

TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity

Abstract

Disclosure of Potential Conflicts of Interest

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature